Abstract
Background: Disseminated intravascular coagulation (DIC) is a known complication of malignancy. Drug-induced DIC is also reported. Sunitinib is a tyrosine kinase inhibitor approved as an oral targeted therapy in the treatment of different cancers. Here we present a case study of disseminated intravascular coagulation following the administration of Sunitinib after COVID-19 infection in a patient diagnosed with metastatic neuroendocrine tumor of the lung.
Case Report: A 35-year-old male patient with a known metastatic lung neuroendocrine tumor (NET) who was treated with Sunitinib for many years with partial response and tolerating the treatment well-developed recurrent DIC on Sunitinib after COVID-19 infection.
Discussion: COVID-19 infection is reported to be associated with endothelial injury and inflammation. Vascular endothelial growth factor (VEGF) receptors have a role in the protection and modulation of endothelium. Sunitinib is a multikinase inhibitor with anti- VEGF effect. It is possible that endothelial injury after COVID-19 may have triggered recurrent DIC in this patient who had previously tolerated the same drug without problems.
Conclusion:
DIC may be underreported especially with antineoplastics having anti-VEGF effects. Potential risk, interaction, and association with COVID-19 infection in the Era of the pandemic are unclear but warrants further research, and drug-induced DIC should be considered in the differential diagnosis of such cases.
Keywords: DIC, COVID-19, Sunitinib, Drug, Neuroendocrine, Carcinoma.
New Emirates Medical Journal
Title:Sunitinib Induced Disseminated Intravascular Coagulation after COVID-19 Infection in a Patient with Neuroendocrine Tumor: A Case Report
Volume: 5
Author(s): Mona Tareen, Julieta O Zuluaga, Maroun El khoury, Sameh Salem and Faraz Khan*
Affiliation:
- Department of Hematology/Oncology, American Hospital, Dubai, United Arab Emirates
Keywords: DIC, COVID-19, Sunitinib, Drug, Neuroendocrine, Carcinoma.
Abstract:
Background: Disseminated intravascular coagulation (DIC) is a known complication of malignancy. Drug-induced DIC is also reported. Sunitinib is a tyrosine kinase inhibitor approved as an oral targeted therapy in the treatment of different cancers. Here we present a case study of disseminated intravascular coagulation following the administration of Sunitinib after COVID-19 infection in a patient diagnosed with metastatic neuroendocrine tumor of the lung.
Case Report: A 35-year-old male patient with a known metastatic lung neuroendocrine tumor (NET) who was treated with Sunitinib for many years with partial response and tolerating the treatment well-developed recurrent DIC on Sunitinib after COVID-19 infection.
Discussion: COVID-19 infection is reported to be associated with endothelial injury and inflammation. Vascular endothelial growth factor (VEGF) receptors have a role in the protection and modulation of endothelium. Sunitinib is a multikinase inhibitor with anti- VEGF effect. It is possible that endothelial injury after COVID-19 may have triggered recurrent DIC in this patient who had previously tolerated the same drug without problems.
Conclusion:
DIC may be underreported especially with antineoplastics having anti-VEGF effects. Potential risk, interaction, and association with COVID-19 infection in the Era of the pandemic are unclear but warrants further research, and drug-induced DIC should be considered in the differential diagnosis of such cases.
Export Options
About this article
Cite this article as:
Tareen Mona, Zuluaga O Julieta, El khoury Maroun, Salem Sameh and Khan Faraz*, Sunitinib Induced Disseminated Intravascular Coagulation after COVID-19 Infection in a Patient with Neuroendocrine Tumor: A Case Report, New Emirates Medical Journal 2024; 5 : e140723218725 . https://dx.doi.org/10.2174/0250688204666230714110831
DOI https://dx.doi.org/10.2174/0250688204666230714110831 |
Print ISSN 0250-6882 |
Publisher Name Bentham Science Publisher |
Online ISSN 0250-6882 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Experimental Antiarrhythmic Targets: CaMKII Inhibition – Ready for Clinical Evaluation?
Current Medicinal Chemistry Biomarkers and Multiple Drug Resistance in Breast Cancer
Current Cancer Drug Targets Recent Advances in Methodologies for the Discovery of Antimycobacterial Drugs
Current Bioactive Compounds Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Molecular Mechanism and Targets of the Antimicrobial Activity of Metal Nanoparticles
Current Topics in Medicinal Chemistry Chemometric Studies on Potential Larvicidal Compounds Against Aedes Aegypti
Medicinal Chemistry Activatable Optical Probes for the Detection of Enzymes
Current Organic Synthesis Meet the Section Editor
Current Drug Safety Human ACE-2, MCP1 and micro-RNA 146 as Novel Markers for COVID- 19 Affection and Severity
Infectious Disorders - Drug Targets Assessment of Functional and Biological Compatibility of Antenna in a Head-Mountable DBS Device Using a Rat Model
Neuroscience and Biomedical Engineering (Discontinued) A Brief Review of Radiofrequency Coils for Cardiac Magnetic Resonance Imaging and Spectroscopy
Current Medical Imaging Synthesis of Four Heterocyclic Drug Molecules Repurposed for COVID-19
Mini-Reviews in Organic Chemistry Patents Related to Pathogenic Human Coronaviruses
Recent Patents on Biotechnology Healthcare Expenditures Related to BMI and Physical Activity Among Diabetic Older People: Cross-sectional Analysis of Sabe Study
Current Diabetes Reviews Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally Sampled Pharmacophore Approach
Current Computer-Aided Drug Design Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Sodium Channel Blocking Activity and In-vivo Testing of New Phenylimidazole Derivatives
Letters in Drug Design & Discovery Exploring Mode of Phosphoramidon and Aβ Peptide Binding to hECE-1 by Molecular Dynamics and Docking Studies
Protein & Peptide Letters (Q)SAR Studies to Design New Human Choline Kinase Inhibitors as Antiproliferative Drugs
Current Medicinal Chemistry Recent Trends in Tubulin-Binding Combretastatin A-4 Analogs for Anticancer Drug Development
Current Medicinal Chemistry